論文リストについては、以下のPDFをご覧ください。
以下、2021年3月現在
1: Ye W, Ascher-Svanum H, Flynn JA, Tanji Y, Takahashi M. Predictors of
antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of
schizophrenia patients in Japan. Clinicoecon Outcomes Res. 2012;4:13-9. doi:
10.2147/CEOR.S25968. Epub 2012 Jan 13. PMID: 22347801; PMCID: PMC3278200.
2: Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M, Conley RR.
Antipsychotic monotherapy among outpatients with schizophrenia treated with
olanzapine or risperidone in Japan: a health care database analysis.
Neuropsychiatr Dis Treat. 2012;8:259-66. doi: 10.2147/NDT.S25662. Epub 2012 Jun
18. PMID: 22745559; PMCID: PMC3385585.
3: Ye W, Ascher-Svanum H, Tanji Y, Flynn JA, Takahashi M. Predictors of
continuation with olanzapine during the 1-year naturalistic treatment of
patients with schizophrenia in Japan. Patient Prefer Adherence. 2011;5:611-7.
doi: 10.2147/PPA.S26002. Epub 2011 Dec 14. PMID: 22259238; PMCID: PMC3259076.
4: Novick D, Ascher-Svanum H, Haro JM, Bertsch J, Takahashi M. Schizophrenia
Outpatient Health Outcomes study: twelve-month findings. Pragmat Obs Res. 2012
Jun 6;3:27-40. doi: 10.2147/POR.S26552. PMID: 27774015; PMCID: PMC5045007.
5: Takahashi M, Nakahara N, Fujikoshi S, Iyo M. Remission, response, and relapse
rates in patients with acute schizophrenia treated with olanzapine monotherapy
or other atypical antipsychotic monotherapy: 12-month prospective observational
study. Pragmat Obs Res. 2015 Jul 14;6:39-46. doi: 10.2147/POR.S64973. PMID:
27774031; PMCID: PMC5045023.
6: Takahashi M, Takita Y, Goto T, Ichikawa H, Saito K, Matsumoto H, Tanaka Y. An
open-label, dose-titration tolerability study of atomoxetine hydrochloride in
Japanese adults with attention-deficit/hyperactivity disorder. Psychiatry Clin
Neurosci. 2011 Feb;65(1):55-63. doi: 10.1111/j.1440-1819.2010.02159.x. PMID:
21265936.
7: Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Efficacy and
safety of olanzapine in the treatment of Japanese patients with bipolar I
disorder in a current manic or mixed episode: a randomized, double-blind,
placebo- and haloperidol-controlled study. J Affect Disord. 2012
Feb;136(3):476-84. doi: 10.1016/j.jad.2011.10.045. Epub 2011 Nov 30. PMID:
22134043.
8: Katagiri H, Takita Y, Tohen M, Higuchi T, Kanba S, Takahashi M. Safety and
efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in
18-week treatment of manic/mixed episodes for Japanese patients with bipolar I
disorder. Curr Med Res Opin. 2012 May;28(5):701-13. doi:
10.1185/03007995.2012.666961. Epub 2012 Apr 10. PMID: 22356118.
9: Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T.
Improved outcomes following a switch to olanzapine treatment from risperidone
treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Psychiatry Clin Neurosci. 2012 Jun;66(4):313-21. doi:
10.1111/j.1440-1819.2012.02351.x. PMID: 22624736.
10: Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez
JC. A randomized, double-blind, placebo-controlled study of rapid-acting
intramuscular olanzapine in Japanese patients for schizophrenia with acute
agitation. BMC Psychiatry. 2013 Jan 11;13:20. doi: 10.1186/1471-244X-13-20.
Erratum in: BMC Psychiatry. 2014;14:313. Erratum in: BMC Psychiatry.
2014;14:313. PMID: 23311957; PMCID: PMC3556331.
11: Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi
M, Gomez JC. Efficacy and safety of olanzapine for treatment of patients with
bipolar depression: Japanese subpopulation analysis of a randomized, double-
blind, placebo-controlled study. BMC Psychiatry. 2013 May 14;13:138. doi:
10.1186/1471-244X-13-138. PMID: 23672672; PMCID: PMC3666902.
12: Takahashi M, Goto T, Takita Y, Chung SK, Wang Y, Gau SS. Open-label, dose-
titration tolerability study of atomoxetine hydrochloride in Korean, Chinese,
and Taiwanese adults with attention-deficit/hyperactivity disorder. Asia Pac
Psychiatry. 2014 Mar;6(1):62-70. doi: 10.1111/j.1758-5872.2012.00204.x. Epub
2012 Jul 23. PMID: 23857916.
13: Goto T, Hirata Y, Takita Y, Trzepacz PT, Allen AJ, Song DH, Gau SS, Ichikawa
H, Takahashi M. Efficacy and Safety of Atomoxetine Hydrochloride in Asian Adults
With ADHD. J Atten Disord. 2017 Jan;21(2):100-109. doi:
10.1177/1087054713510352. Epub 2016 Jul 28. PMID: 24203774.
14: Hirata Y, Goto T, Takita Y, Trzepacz PT, Allen AJ, Ichikawa H, Takahashi M.
Long-term safety and tolerability of atomoxetine in Japanese adults with
attention deficit hyperactivity disorder. Asia Pac Psychiatry. 2014
Sep;6(3):292-301. doi: 10.1111/appy.12119. Epub 2013 Dec 25. PMID: 24376099.
15: Katagiri H, Tohen M, McDonnell DP, Fujikoshi S, Case M, Kanba S, Takahashi
M, Gomez JC. Safety and efficacy of olanzapine in the long-term treatment of
Japanese patients with bipolar I disorder, depression: an integrated analysis.
Psychiatry Clin Neurosci. 2014 Jul;68(7):498-505. doi: 10.1111/pcn.12156. Epub
2014 Mar 4. PMID: 24417745.
16: Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T. One-
year outcomes in schizophrenia after switching from typical antipsychotics to
olanzapine in Japan: an observational study. Pragmat Obs Res. 2012 Jun
13;3:41-49. doi: 10.2147/POR.S28008. PMID: 27774016; PMCID: PMC5045008.
17: Katagiri H, Fujikoshi S, Suzuki T, Fujita K, Sugiyama N, Takahashi M, Gomez
JC. Erratum: A randomized, double-blind, placebo-controlled study of rapid-
acting intramuscular olanzapine in Japanese patients for schizophrenia with
acute agitation. BMC Psychiatry. 2014 Dec 10;14:313. doi:
10.1186/s12888-014-0313-9. Erratum for: BMC Psychiatry. 2013;13:20. PMID:
25927447; PMCID: PMC4260377.
18: Lee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW, Park TW, Yook KH, Lee
JI, Bahn GH, Hirata Y, Goto T, Takita Y, Takahashi M, Lee S, Treuer T. Efficacy
and safety of atomoxetine hydrochloride in Korean adults with attention-deficit
hyperactivity disorder. Asia Pac Psychiatry. 2014 Dec;6(4):386-96. doi:
10.1111/appy.12160. Epub 2014 Oct 27. PMID: 25345739.
19: Takahashi M, Takita Y, Yamazaki K, Hayashi T, Ichikawa H, Kambayashi Y,
Koeda T, Oki J, Saito K, Takeshita K, Allen AJ. A randomized, double-blind,
placebo-controlled study of atomoxetine in Japanese children and adolescents
with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol.
2009 Aug;19(4):341-50. doi: 10.1089/cap.2008.0154. PMID: 19702486.
1. Progress in Psychopharmacology(8)リチウムの作用機序
高橋 道宏
分子精神医学 2(4), 392-395, 2002-10
2. 抗うつ薬の分子薬理作用からみた大うつ病の病態メカニズム (特集 気分障害–分子生物学的アプローチの最新現況報告)
高橋 道宏
分子精神医学 1(2), 145-150, 2001-03
3. 抗うつ薬・ストレスの及ぼすラット脳内 calcineurin mRNA 発現への影響
森信 繁 , 藤巻 康一郎 , 高橋 道宏 , 大谷 浩一 , 加藤 進昌
日本神経精神薬理学雑誌 = Japanese journal of psychopharmacology 18(6), 389, 1998-12-25
4. 感情障害発病に関わるcAMP情報伝達機能変化と遺伝子発現変化 : ストレス・抗うつ薬とBDNF mRNA発現との関連
森信 繁 , 藤巻 康一郎 , 高橋 道宏 , 十束 支朗
精神神經學雜誌 = Psychiatria et neurologia Japonica 98(11), 937-942, 1996-11-25
5. 注意欠陥/多動性障害治療薬 ストラテラカプセル (新薬展望2010) — (注目の新薬)
高橋 道宏 , 丹治 由佳
医薬ジャ-ナル 46(S1), 64-69, 2010
6. 日本人ADHD患者におけるアトモキセチンの有効性と安全性 : 短期プラセボ対照二重盲検試験および長期継続投与試験のまとめ
後藤 太郎 , 多喜田 保志 , 高橋 道宏
小児の精神と神経 50(4), 459-460, 2010-12-30
7. ストラテラ開発の歴史と製剤特性 (ADHD薬物療法の新時代–コンサータとストラテラ) — (ストラテラに関する知識と経験)
後藤 太郎 , 丹治 由佳 , 高橋 道宏
現代のエスプリ (513), 155-163, 2010-04
8. The UKU side effect rating scale(UKU副作用評価尺度)日本語版およびその作成経緯
千葉 茂 , 高橋 道宏
臨床精神薬理 8(12), 1939-1961, 2005-12
